免疫治疗护理标准

International Journal of Pulmonary & Respiratory Sciences Pub Date : 2019-10-10 DOI:10.19080/ijoprs.2019.04.555633

F. Griesinger

{"title":"免疫治疗护理标准","authors":"F. Griesinger","doi":"10.19080/ijoprs.2019.04.555633","DOIUrl":null,"url":null,"abstract":"Lung cancer ist the most frequent deadly malignant disease in men and the second most deadly malignant disease in women [1]. Two â€œleapâ€ innovations, the detection of driver mutations in about 25% of patients and the observation that NSCLC is an immune-checkpoint-inhibitor responsive disease leading to a dramatic improvement in ORR, PFS and OS, therapeutic standards in NSCLC have changed dramatically over the past decade [2].","PeriodicalId":257243,"journal":{"name":"International Journal of Pulmonary & Respiratory Sciences","volume":"17 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2019-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Immune-Therapy Standards Of Care\",\"authors\":\"F. Griesinger\",\"doi\":\"10.19080/ijoprs.2019.04.555633\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Lung cancer ist the most frequent deadly malignant disease in men and the second most deadly malignant disease in women [1]. Two â€œleapâ€ innovations, the detection of driver mutations in about 25% of patients and the observation that NSCLC is an immune-checkpoint-inhibitor responsive disease leading to a dramatic improvement in ORR, PFS and OS, therapeutic standards in NSCLC have changed dramatically over the past decade [2].\",\"PeriodicalId\":257243,\"journal\":{\"name\":\"International Journal of Pulmonary & Respiratory Sciences\",\"volume\":\"17 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-10-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Pulmonary & Respiratory Sciences\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.19080/ijoprs.2019.04.555633\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Pulmonary & Respiratory Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.19080/ijoprs.2019.04.555633","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

肺癌是男性最常见的致命恶性疾病，也是女性第二大致命恶性疾病[1]。两项创新:在约25%的患者中检测到驱动突变，以及观察到非小细胞肺癌是一种免疫检查点抑制剂反应性疾病，导致ORR、PFS和OS的显着改善，在过去十年中，非小细胞肺癌的治疗标准发生了巨大变化[2]。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Immune-Therapy Standards Of Care

Lung cancer ist the most frequent deadly malignant disease in men and the second most deadly malignant disease in women [1]. Two â€œleapâ€ innovations, the detection of driver mutations in about 25% of patients and the observation that NSCLC is an immune-checkpoint-inhibitor responsive disease leading to a dramatic improvement in ORR, PFS and OS, therapeutic standards in NSCLC have changed dramatically over the past decade [2].

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

International Journal of Pulmonary & Respiratory Sciences

自引率

0.00%

发文量